| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/13/2001 | US6201140 7-0-ethers of taxane derivatives |
| 03/13/2001 | US6201133 Certain cyclic thio substituted acylaminoacid amide derivatives |
| 03/13/2001 | US6201132 Inhibitors of membrane-bound serine protease; aminoacyl compounds |
| 03/13/2001 | US6201130 N-arylsulfonylamino acid omega-amides |
| 03/13/2001 | US6201129 Anticarcinogenic agents |
| 03/13/2001 | US6201111 Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors |
| 03/13/2001 | US6201105 Amino acid sequence; treatment of septic shock and cachexia; diagnosis |
| 03/13/2001 | US6201104 Amino acid sequences of angiogenesis-inhibiting protein receptor; drug screening; isolation of angiogenesis related proteins |
| 03/13/2001 | US6201072 Block copolymers of polyether and polyester |
| 03/13/2001 | US6201020 Effective poly(adenosine 5'-diphospho-ribose) polymerase (parp) inhibitor for treatment of tissue damage by necrosis or apoptosis; side effect reduction |
| 03/13/2001 | US6201019 Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same |
| 03/13/2001 | US6201001 Tubulin polymerization inhibitors; anticarcinogenic agents |
| 03/13/2001 | US6200993 Heterosubstituted pyridine derivatives as PDE4 inhibitors |
| 03/13/2001 | US6200992 Administering 1h-1,2,4-triazole derivative, chemotherapeutic agent, and potentiator; anticarcinogenic, antitumor agents |
| 03/13/2001 | US6200989 Administering as urokinase plasminogen activator antagonists, antitumor and antimetastasis agents |
| 03/13/2001 | US6200985 Rapamycin derivatives |
| 03/13/2001 | US6200981 For treating inflammatory diseases such as asthma, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial ischaemia, cystic fibrosis, arthereosclerosis, restenosis, peridontal disease, septic shock, osteoarthritis |
| 03/13/2001 | US6200968 Particle-forming compositions containing fused pyrrolocarbazoles |
| 03/13/2001 | US6200960 Inhibition of proliferation of cells |
| 03/13/2001 | US6200957 Useful for treatment of variety of sex-hormone related and other conditions in both men and women |
| 03/13/2001 | US6200780 Human interferon-ε(IFN-ε), a type I interferon |
| 03/13/2001 | US6200775 Nucleotide sequence coding a polypeptide associated with the diagnosis and treatment of infections |
| 03/13/2001 | US6200765 Diagnosing tumors in humans; determine the ratio of prostate gland tissue and a random tissue in sample, amplified amount of prostate tissues in sample indicates, tumors |
| 03/13/2001 | US6200763 Detecting cell expressing myeloid polypeptide; incubate cell with binding substance and detecting bound substance, presence of bound protein indicates cell expressing myeloid protein |
| 03/13/2001 | US6200599 Ortho ester lipids |
| 03/13/2001 | US6200598 Active materials entrapped within liposome interior |
| 03/13/2001 | US6200567 An antibody that binds to the common beta c chain of the receptor for gm-csf, il-3 and il-5 |
| 03/13/2001 | US6200566 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| 03/13/2001 | US6200547 Carrier including particles that include iron and carbon; therapeutic amount of doxorubicin or paclitaxel adsorbed on the particles. |
| 03/13/2001 | US6200546 Gastrin receptor-avid peptide conjugates |
| 03/13/2001 | CA2167651C Biologically highly active bicyclic aromatic compositions; pharmaceutical and cosmetic compositions containing the same and their use |
| 03/13/2001 | CA2033937C Hemihydrate |
| 03/08/2001 | WO2001016604A1 Screening for agents modulating tgf-beta cell signaling |
| 03/08/2001 | WO2001016603A2 Analysis and treatment of body weight and eating disorders |
| 03/08/2001 | WO2001016365A1 Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
| 03/08/2001 | WO2001016347A1 The hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from panax ginseng |
| 03/08/2001 | WO2001016344A1 Modified adenoviral fibre and uses thereof |
| 03/08/2001 | WO2001016343A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 03/08/2001 | WO2001016335A2 Stromelysin-homologous novel mmp-27 matrix metalloproteinase |
| 03/08/2001 | WO2001016331A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 03/08/2001 | WO2001016317A2 Polycyclic aromatic hydrocarbon induced molecules |
| 03/08/2001 | WO2001016314A1 Iren protein, its preparation and use |
| 03/08/2001 | WO2001016312A2 Nucleic acid based modulators of gene expression |
| 03/08/2001 | WO2001016304A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 03/08/2001 | WO2001016300A2 Method of identifying inhibitors of cdc25 |
| 03/08/2001 | WO2001016299A1 Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders |
| 03/08/2001 | WO2001016296A2 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 03/08/2001 | WO2001016171A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 03/08/2001 | WO2001016170A2 Card proteins involved in cell death regulation |
| 03/08/2001 | WO2001016165A2 Apoptin-associating protein |
| 03/08/2001 | WO2001016156A1 Attractin-like polynucleotides, polypeptides, and antibodies |
| 03/08/2001 | WO2001016139A1 Androgen receptor modulator compounds and methods |
| 03/08/2001 | WO2001016138A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 03/08/2001 | WO2001016137A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 03/08/2001 | WO2001016136A2 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/08/2001 | WO2001016135A2 Reverse-turn mimetics and methods relating thereto |
| 03/08/2001 | WO2001016133A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 03/08/2001 | WO2001016130A1 Substituted indolinones as tyrosine kinase inhibitors |
| 03/08/2001 | WO2001016123A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
| 03/08/2001 | WO2001016122A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| 03/08/2001 | WO2001016114A2 Heterocyclic compounds and methods for modulating cxcr3 function |
| 03/08/2001 | WO2001016108A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 03/08/2001 | WO2001016106A1 Benzamide formulation with histone deacetylase inhibitor activity |
| 03/08/2001 | WO2001016099A1 VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2α-POSITION |
| 03/08/2001 | WO2001016097A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 03/08/2001 | WO2001016091A1 Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 03/08/2001 | WO2001015755A2 Methods and compositions for delivery of pharmaceutical agents |
| 03/08/2001 | WO2001015746A1 Radiopharmaceutical products and their preparation procedure |
| 03/08/2001 | WO2001015745A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | WO2001015730A1 DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 03/08/2001 | WO2001015729A1 Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses |
| 03/08/2001 | WO2001015722A2 Methods useful in affecting apoptosis |
| 03/08/2001 | WO2001015721A1 Novel uses of semaphorin and vegf |
| 03/08/2001 | WO2001015707A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 03/08/2001 | WO2001015704A1 Medicaments that contain xenogenic oligo- or/and polyribonucleotides |
| 03/08/2001 | WO2001015694A1 Extended duration light activated cancer therapy |
| 03/08/2001 | WO2001015692A1 Methods and compositions for selective cancer chemotherapy |
| 03/08/2001 | WO2001015691A1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 03/08/2001 | WO2001015689A1 Use of amino acids for making medicines for treating to insulin-resistance |
| 03/08/2001 | WO2001015679A2 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
| 03/08/2001 | WO2001015675A2 Use of docetaxel for treating hepatocellular carcinoma |
| 03/08/2001 | WO2001015554A1 Metal-containing compositions, preparations and uses |
| 03/08/2001 | WO2001015531A1 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 03/08/2001 | WO2001000848A8 Useful polypeptide |
| 03/08/2001 | WO2000077184A9 Caspase-8 crystals, models and methods |
| 03/08/2001 | WO2000063202A3 BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS |
| 03/08/2001 | WO2000062767A3 Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion |
| 03/08/2001 | WO2000061766A3 Telomerase-specific cancer vaccine |
| 03/08/2001 | WO2000061624A8 48 human secreted proteins |
| 03/08/2001 | WO2000059448A3 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 03/08/2001 | WO2000057861A3 Use of cytidine derivatives for the treatment of leukaemia |
| 03/08/2001 | WO2000054762A3 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 03/08/2001 | WO2000039283A8 Use of cd40 engagement to alter t cell receptor usage |
| 03/08/2001 | WO2000038786A3 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 03/08/2001 | WO2000020447A8 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| 03/08/2001 | WO2000018961A3 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 03/08/2001 | WO1999065449A8 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
| 03/08/2001 | CA2403243A1 Nucleic acid based modulators of gene expression |
| 03/08/2001 | CA2391844A1 Method and formula for tumor remission and suppression of cancer |
| 03/08/2001 | CA2384435A1 Bicyclic androgen and progesterone receptor modulator compounds and methods |